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therapies, bacteriophage cocktails. The value of such approaches
as well as the regulatory pathways are not clear yet. Poten-
tiating strategies have seen a resurgence in recent years and
are focused on blocking speciﬁc resistance mechanisms such as
beta-lactamases, resistance-regulating determinants, preventing
transfer of resistance plasmids or on protecting the microbiome,
disrupting bioﬁlms, targeting dormant bacteria, blocking virulence
factors, or supporting the immune system. In response to relaxed
regulatory requirements and economic incentives, recent years
have seen a trend towards reviving old drugs (e.g. fosfomycin,
fusidic acid, minocycline, aztreonam), modifying old drugs (e.g.
colistin) or potentiating old drugs (e.g. combination of approved
drugs, ß-lactamase-inhibitor combinations). These approacheswill
not solve our major problems with resistant bacteria but may buy
some time.
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Abstract: Antibiotic resistance can develop quickly. The CDC
demonstrated in2013 that theﬁrst reported cases of bacterial resis-
tance occurred in less than three years after market introduction of
sixkeyantibiotics. Yet antibiotic innovation isprogressingat amore
sedate pace, with only seven new classes of antibiotics launched
between 2000 and 2014 (Laxminarayan 2014). One reason for this
mismatch is that the pharmaceutical industry is not incentivized
to develop new antibiotics. Existing, generic antibiotics are inex-
pensive and still generally effective. New classes of antibiotics are
often necessary for only a small number of patients or as an insur-
ance mechanism for potential future outbreaks, making the return
on the sizeable investments in research and development insigniﬁ-
cant or negative. These poor returns encourage the pharmaceutical
industry to focus their efforts elsewhere. Yet resistance continues
to emerge, and if we wait until a major outbreak occurs, given the
long lead-times for developing a new antibiotic, it will be too late.
New incentives are necessary to stimulate greater antibiotic inno-
vation, and they must be linked to the sustainable and appropriate
use of the resulting antibiotic. Otherwise resistance may develop
faster. New incentives need to reward developers for their knowl-
edge generation, not the number of treatments sold. They also need
to ensure that patients receive the necessary antibiotic, regardless
of income status. These are fundamental changes to the current
reward system for pharmaceutical innovation. The EU-ﬁnanced
Innovative Medicines Initiative project, Driving reinvestment in
R&D for antibiotics and advocating their responsible use (DRIVE-
AB), is tasked with identifying new, sustainable economic models
as well as recommendations for a viable path forward to greater
antibiotic innovation.
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Abstract: Pragmatic strategies to improve antibiotic prescrib-
ing will be discussed in this session. Although a whole healthcare
economy approach to antibiotic stewardshipwill be advocated, the
particular focus will be within acute health care. Implementation
and adoption will be considered along with improvement meth-
ods in stewardship. Supporting organisational models will also be
reviewed and practical examples and case studiesdescribed. The
real and potential challenges faced in delivering effective antibiotic
stewardship and sustaining improvement will be discussed.
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Abstract: In recent years, deﬁnitive studies have demonstrated
the efﬁacy of the use of antiretroviral medications for primary
and secondary HIV prevention. The HPTN 052 trial enrolled 1,752
partners in HIV discordant couples in Africa, Asia and the Amer-
icas, and randomized the infected partner to receive immediate
versus deferred antiretroviral therapy. HIV-infected participants
who immediately initiated treatment were more than 96% less
likely to transmit HIV to their partners compared to those in the
delayed arm. The public health beneﬁt of early treatment has been
corroboratedbypopulation level studies correlatingdecreasingHIV
incidence in several areas of southern Africa with access to early
initiation of antiretrovirals. However, since the majority of peo-
ple living with HIV globally are unaware of their infection, and
less than 1/3 are virologically suppressed, new approaches to pri-
mary prevention for high risk seronegatives are also needed. Ten
randomized, controlled trials of antiretroviral pre-exposure pro-
phylaxis (PrEP) have been conducted, with studies in men who
have sex with men, heterosexual discordant couples, and injection
drug users ﬁnding that oral tenofovir-based regimens have been
effective in decreasing HIV incidence. Several studies of PrEP in
youngAfricanwomenhavenotdemonstratedefﬁcacy,while others
have,with variable levels ofmedication adherence explainingmost
